Hamza Hasan

Hamza Hasan's work experience begins with their role as Chief Executive Officer at RoboTrials, a clinical trial technology company specializing in robotic process automation and artificial intelligence. Hamza started in February 2021 and is currently in this position. Previously, they worked at CRISPR Therapeutics as a Clinical Pharmacology Manager, starting in May 2021, and at Regeneron as a Clinical Study Specialist from April 2020 to May 2021. Before that, they were a Research Program Coordinator at The Johns Hopkins University School of Medicine from October 2018 to March 2020. Their earliest work experience was as a Researcher at the New Jersey Institute of Technology from August 2013 to August 2017.

Hamza Hasan has a Master of Science (MS) degree in Biotechnology from The Johns Hopkins University. Hamza also holds a Bachelor of Science (BS) degree in Biology from the New Jersey Institute of Technology. Hamza has completed the HMX Pro & Fundamentals Programs in Immuno-oncology & Immunology at Harvard Medical School. Hamza has taken courses in the Fundamentals of Cancer at The Johns Hopkins University School of Medicine and Methods for Clinical and Translational Research at the Johns Hopkins Bloomberg School of Public Health. Hamza has participated in the National Science Foundation Innovation Corps Program at The Johns Hopkins University.

Additionally, Hamza has obtained various certifications including Basic Human Subjects Research, Clinical Research Coordinator (CRC), Electronic Information Security and Data Management, Good Clinical Practice (GCP), Laboratory Safety / Biosafety Level I & II, and Radiation Safety. All these certifications were obtained from The Johns Hopkins University School of Medicine.